Viewing Study NCT02049593


Ignite Creation Date: 2025-12-25 @ 1:03 AM
Ignite Modification Date: 2025-12-30 @ 12:03 PM
Study NCT ID: NCT02049593
Status: COMPLETED
Last Update Posted: 2022-09-26
First Post: 2014-01-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor: Jonsson Comprehensive Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module